<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app41.us.archive.org';v.server_ms=527;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-10934?contentType=xml', '20180712200233')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20180712200233/https://www.guideline.gov/summaries/downloadcontent/ngc-10934?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20180712200233/https://www.guideline.gov/summaries/downloadcontent/ngc-10934?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-10934?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20180712200233" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20180610072637/https://www.guideline.gov/summaries/downloadcontent/ngc-10934?contentType=xml" title="10 Jun 2018"><strong>Jun</strong></a></td>
		  <td class="c" id="displayMonthEl" title="You are here: 20:02:33 Jul 12, 2018">JUL</td>
		  <td class="f" nowrap="nowrap">Aug</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20180610072637/https://www.guideline.gov/summaries/downloadcontent/ngc-10934?contentType=xml" title="07:26:37 Jun 10, 2018"><img src="/static/images/toolbar/wm_tb_prv_on.png" alt="Previous capture" width="14" height="16" border="0" /></a></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 20:02:33 Jul 12, 2018">12</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap">2017</td>
		  <td class="c" id="displayYearEl" title="You are here: 20:02:33 Jul 12, 2018">2018</td>
		  <td class="f" nowrap="nowrap">2019</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20180712200233*/https://www.guideline.gov/summaries/downloadcontent/ngc-10934?contentType=xml" title="See a list of every capture for this URL">5 captures</a>
	      <div class="r" title="Timespan for captures of this URL">02 Oct 2017 - 12 Jul 2018</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/archiveteam);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/archiveteam" target="_new"><span class="wm-title">Archive Team</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  <img align=right src="http://archiveteam.org/images/e/e6/Archiveteam.jpg" width=200> Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested parties, and has expanded into a large amount of related projects for saving online and digital history.
<p>
History is littered with hundreds of conflicts over the future of a community, group, location or business that were "resolved" when one of the parties stepped ahead and destroyed what was there. With the original point of contention destroyed, the debates would fall to the wayside. Archive Team believes that by duplicated condemned data, the conversation and debate can continue, as well as the richness and insight gained by keeping the materials. Our projects have ranged in size from a single volunteer downloading the data to a small-but-critical site, to over 100 volunteers stepping forward to acquire terabytes of user-created data to save for future generations.
<p>
The main site for Archive Team is at <a href="http://www.archiveteam.org">archiveteam.org</a> and contains up to the date information on various projects, manifestos, plans and walkthroughs.
<p>
This collection contains the output of many Archive Team projects, both ongoing and completed. Thanks to the generous providing of disk space by the Internet Archive, multi-terabyte datasets can be made available, as well as in use by the <a href="http://archive.org/web/web.php">Wayback Machine</a>, providing a path back to lost websites and work. 
<p>
Our collection has grown to the point of having sub-collections for the type of data we acquire. If you are seeking to browse the contents of these collections, the Wayback Machine is the best first stop. Otherwise, you are free to dig into the stacks to see what you may find.
<p>
<b>The Archive Team Panic Downloads</b> are full pulldowns of currently extant websites, meant to serve as emergency backups for needed sites that are in danger of closing, or which will be missed dearly if suddenly lost due to hard drive crashes or server failures. 
<p>
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/archivebot)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/archivebot" target="_new"><span class="wm-title">ArchiveBot: The Archive Team Crowdsourced Crawler</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  ArchiveBot is an IRC bot designed to automate the archival of smaller websites (e.g. up to a few hundred thousand URLs). You give it a URL to start at, and it grabs all content under that URL, records it in a WARC, and then uploads that WARC to ArchiveTeam servers for eventual injection into the Internet Archive (or other archive sites).
<p>
To use ArchiveBot, drop by #archivebot on EFNet. To interact with ArchiveBot, you issue commands by typing it into the channel. Note you will need channel operator permissions in order to issue archiving jobs. The dashboard shows the sites being downloaded currently.
<p>
There is a dashboard running for the archivebot process at <a href="http://www.archivebot.com">http://www.archivebot.com</a>.
<p>
ArchiveBot's source code can be found at <a href="https://github.com/ArchiveTeam/ArchiveBot">https://github.com/ArchiveTeam/ArchiveBot</a>.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-10934?contentType=xml","2018-07-12",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>The role of biopsy in the management of patients with presumed diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Ragel BT, Ryken TC, Kalkanis SN, Ziu M, Cahill D, Olson JJ. The role of biopsy in the management of patients with presumed diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015 Dec;125(3):481-501. [64 references] <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26530259&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The rating schemes used for the strength of the evidence (<strong>Class I-III</strong>) and the levels of recommendations (<strong>Level I-III</strong>) are defined at the end of the &quot;Major Recommendations&quot; field.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Question</span></strong> </p>
<p>What is the optimal role of biopsy in the initial management of presumptive low-grade glioma in adults?</p>
<p><strong>Target Population</strong> </p>
<p>Adult patients with imaging suggestive of a low-grade glioma.</p>
<p><strong>Recommendation</strong></p>
<p><em>Level III</em>. Stereotactic biopsy is recommended when definitive surgical resection is limited by lesions that are deep-seated, not resectable, and/or located within eloquent cortex, or in patients unable to undergo craniotomy due to medical co-morbidities to obtain the critical tissue diagnosis needed for targeted treatment planning for patients with low-grade gliomas. </p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Question</span></strong> </p>
<p>What is the best technique for brain biopsy?</p>
<p><strong>Target Population</strong> </p>
<p>Adult patients with imaging suggestive of a low-grade glioma.</p>
<p><strong>Recommendation</strong></p>
<p><em>Level III</em>. Frameless and frame-based stereotactic brain biopsy (SBB) for low-grade gliomas are recommended based on clinical circumstances as they provide similar diagnostic yield, diagnostic accuracy, morbidity, and mortality. It is recommended the surgeon consider advanced imaging techniques (e.g., perfusion, spectroscopy, metabolic studies) to target specific regions of interest to potentially improve diagnostic accuracy. </p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Definitions</span></strong></p>
<p><strong>American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Classification of Evidence and Levels of Recommendation on Diagnosis</strong></p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Classification of Evidence and Levels of Recommendation on Diagnosis&quot;>
    <tbody>
        <tr>
            <th valign=&quot;top&quot; style=&quot;font-weight: bold; text-align: center;&quot; scope=&quot;row&quot;>Class I evidence/Level I (or A) recommendation </th>
            <td valign=&quot;top&quot;>Evidence provided by one or more well-designed clinical studies of a <em>diverse</em> population using a &quot;gold standard&quot; reference test in a blinded evaluation appropriate for the diagnostic applications and enabling the assessment of sensitivity, specificity, positive and negative predictive values, and, where applicable, likelihood ratios</td>
        </tr>
        <tr>
            <th valign=&quot;top&quot; style=&quot;font-weight: bold; text-align: center;&quot; scope=&quot;row&quot;>Class II evidence/Level II (or B) recommendation </th>
            <td valign=&quot;top&quot;>Evidence provided by one or more well-designed clinical studies of a <em>restricted</em> population using a &quot;gold standard&quot; reference test in a blinded evaluation appropriate for the diagnostic applications and enabling the assessment of sensitivity, specificity, positive and negative predictive values, and, where applicable, likelihood ratios</td>
        </tr>
        <tr>
            <th valign=&quot;top&quot; style=&quot;font-weight: bold; text-align: center;&quot; scope=&quot;row&quot;>Class III evidence/Level III (or C) recommendation </th>
            <td valign=&quot;top&quot;>Evidence provided by expert opinion or studies that do not meet the criteria for the delineation of sensitivity, specificity, positive and negative predictive values, and, where applicable, likelihood ratios</td>
        </tr>
    </tbody>
</table></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Diffuse low grade glioma </p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Diagnosis"/>
      <fieldvalue value="Evaluation"/>
      <fieldvalue value="Management"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Neurological Surgery"/>
      <fieldvalue value="Neurology"/>
      <fieldvalue value="Oncology"/>
      <fieldvalue value="Pathology"/>
      <fieldvalue value="Radiology"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To evaluate relevant literature to formulate useful guidelines for the role of stereotactic brain biopsy (SBB) in the initial diagnosis of presumed low grade glioma (i.e., astrocytomas, oligodendrogliomas, and mixed oligo-astrocytomas)</p></div>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Adult patients with imaging suggestive of a low-grade glioma</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Stereotactic brain biopsy (SBB) (frameless and frame-based) </li>
    <li>Advanced imaging techniques (e.g., perfusion, spectroscopy, metabolic studies to target specific regions of interest) </li>
</ol>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Morbidity </li>
    <li>Mortality </li>
    <li>Diagnostic accuracy </li>
    <li>Diagnostic yield </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Hand-searches of Published Literature (Primary Sources)"/>
      <fieldvalue value="Hand-searches of Published Literature (Secondary Sources)"/>
      <fieldvalue value="Searches of Electronic Databases"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong><span style=&quot;text-decoration: underline;&quot;>General Search Strategy</span></strong></p>
<p><strong>Literature Examination Approach</strong></p>
<p>A wide-ranging literature search strategy was undertaken to identify all citations relevant to the management of low grade gliomas. The MEDLINE and EMBASE electronic databases were searched from 1990 through 2012, with additional data being gleaned from the Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Registry, and Cochrane Database of Abstracts of Reviews of Effects. The search strategies used a combination of subheadings and text words with the specifics of this work being outlined in each guideline section. Reference lists of the publications chosen for full text review were also screened for potentially relevant studies.</p>
<p><strong>Study Selection </strong></p>
<p>The search of the bibliographic databases identified possibly relevant citations for a given topic and often these were large in number. The eligibility (inclusion/exclusion) criteria to screen the citations for each of the questions were determined ahead of time for each section by the writing group. At least two authors evaluated the titles and abstracts using the inclusion and exclusion criteria with broad interpretation of the criteria being used initially so as to maximize the likelihood of capturing pertinent information. Cases of disagreement about pertinence were resolved by a third author when needed. The full text articles of the selected abstracts were then collected and the same process of applying the eligibility criteria was carried out again with the more in depth information available. Articles that met the eligibility criteria were grouped according to the questions they addressed and used to create the evidence tables and scientific foundation sections. Reasons for exclusion for papers were also documented so as to be able to discuss pertinent problem citations in the scientific foundation as needed.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Specific Search Strategy for This Guideline</span></strong></p>
<p>Cochrane Central Register of Controlled Trials, the Cochrane Review, PubMed, and EMBASE literature searches from January 1, 1990, to December 31, 2012, encompassing &quot;all fields&quot; or &quot;search all text&quot; utilizing search strings to identify pertinent literature on biopsy of low grade glioma were undertaken. For PubMed the following search terms were used: low-grade glioma biopsy, LGG biopsy, stereotactic brain biopsy, brain biopsy sampling error, brain biopsy sampling errors, low-grade glioma sample error, and low-grade glioma sampling errors. For the Cochrane Central Register of Controlled Trials and EMBASE the following search terms were used: biopsy/and brain neoplasms/, brain neoplasms/and stereotactic techniques/, glioma/and stereotactic techniques/, and glioma/and biopsy. For the Cochrane Library the following search terms were used: low-grade glioma biopsy, stereotactic brain biopsy, biopsy and brain neoplasm, brain neoplasms and stereotactic techniques, glioma and stereotactic technique, and glioma and biopsy.</p>
<p><strong>Eligibility Criteria</strong></p>
<p>For literature to be included for consideration, the paper had to include adults (i.e., age 18 and above), with the following exclusion criteria:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Non-English publications </li>
    <li>Basic science papers </li>
    <li>Animal studies </li>
    <li>Papers dedicated to pediatric gliomas (i.e., age less than 18) </li>
    <li>Papers describing only malignant or high-grade glioma (glioblastoma multiforme; GBM) </li>
    <li>Papers describing recurrent gliomas (recurrent astrocytoma, progressive astrocytoma) </li>
    <li>Papers focusing exclusively on surgery, chemotherapy, radiation or anesthesia, stereotactic guided surgical (e.g., stereotactic resection of arteriovenous malformation), psychiatric, infectious (e.g., acquired immunodeficiency syndrome [AIDS], human immunodeficiency virus [HIV], abscess, fungal), vascular, pathologic analysis (e.g., immunohistochemical staining), and spinal cord tumors </li>
</ul>
<p>Because the published literature lacks large series of patients with presumed low grade glioma undergoing targeted stereotactic biopsies directed by advanced imaging modalities (e.g., perfusion, single-photon positron emission tomography [SPECT]), small cases series of fewer than 25 patients were included.</p>
<p><strong>Study Selection</strong></p>
<p>Following broad screening for relevance, two independent reviewers evaluated citations and full-text screening of potentially relevant papers using a priori criteria for data extraction on a standardized form. Disagreements were resolved with the involvement of a third reviewer, followed by primary re-review until agreement was achieved.</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>An initial literature search resulted in 5800 articles. Exclusion criteria were applied to titles and abstracts resulting in 123 articles that underwent full-text review (see Fig. 1 in the original guideline document for a flowchart). A final 63 articles met all inclusion criteria and were used to formulate guidelines.</p></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Weighting According to a Rating Scheme (Scheme Given)"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong><span style=&quot;text-decoration: underline;&quot;>American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Classification of Evidence and Levels of Recommendation on Diagnosis</span></strong></p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Classification of Evidence and Levels of Recommendation on Diagnosis&quot;>
    <tbody>
        <tr>
            <th valign=&quot;top&quot; style=&quot;font-weight: bold; text-align: center;&quot; scope=&quot;row&quot;>Class I evidence/Level I (or A) recommendation </th>
            <td valign=&quot;top&quot;>Evidence provided by one or more well-designed clinical studies of a <em>diverse</em> population using a &quot;gold standard&quot; reference test in a blinded evaluation appropriate for the diagnostic applications and enabling the assessment of sensitivity, specificity, positive and negative predictive values, and, where applicable, likelihood ratios</td>
        </tr>
        <tr>
            <th valign=&quot;top&quot; style=&quot;font-weight: bold; text-align: center;&quot; scope=&quot;row&quot;>Class II evidence/Level II (or B) recommendation </th>
            <td valign=&quot;top&quot;>Evidence provided by one or more well-designed clinical studies of a <em>restricted</em> population using a &quot;gold standard&quot; reference test in a blinded evaluation appropriate for the diagnostic applications and enabling the assessment of sensitivity, specificity, positive and negative predictive values, and, where applicable, likelihood ratios</td>
        </tr>
        <tr>
            <th valign=&quot;top&quot; style=&quot;font-weight: bold; text-align: center;&quot; scope=&quot;row&quot;>Class III evidence/Level III (or C) recommendation </th>
            <td valign=&quot;top&quot;>Evidence provided by expert opinion or studies that do not meet the criteria for the delineation of sensitivity, specificity, positive and negative predictive values, and, where applicable, likelihood ratios</td>
        </tr>
    </tbody>
</table></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Systematic Review with Evidence Tables"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong><span style=&quot;text-decoration: underline;&quot;>General Evidence Analysis</span></strong></p>
<p><strong>Quality Assessment and Statistical Methods</strong></p>
<p>Articles that met the eligibility criteria were grouped according to the questions they addressed and used to create the evidence tables and scientific foundation sections. Reasons for exclusion for papers were also documented so as to be able to discuss pertinent problem citations in the scientific foundation as needed.</p>
<p>Studies which met the eligibility criteria were subject to more detailed scrutiny and had their data extracted by one reviewer and the extracted information was checked by one or more other reviewers. Evidence and summary tables, reporting the extracted study information and evidence classification, were generated for all of the included studies for each of the questions. Evidence tables were created with most recent data first and subsequent listings in retrograde chronological order. The table headings consisted of first author name and year, followed by a brief study description, chosen data class and conclusion. The authors were directed to craft the data in the tables in a succinct and fact filled manner so as to allow for understanding of the literature entry. The literature in the evidence tables was expanded upon in the scientific foundation of each section so as to emphasize important points supporting its classification and contribution to recommendations. The method by which this was accomplished is expanded upon in the Joint Guideline Committee Guideline Development Methodology document (see the &quot;Availability of Companion Documents&quot; field). Internal drafts of the tables and manuscripts were developed by sharing between writers electronically, by telephone and meetings. Summary and conclusion statements were included for each section, with comments on key issues for future investigation being added where pertinent.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Specific Evidence Analysis for This Guideline</span></strong></p>
<p><strong>Study Selection and Quality Assessment</strong></p>
<p>Following broad screening for relevance, two independent reviewers evaluated citations and full-text screening of potentially relevant papers using a priori criteria for data extraction on a standardized form. Disagreements were resolved with the involvement of a third reviewer, followed by primary re-review until agreement was achieved. Studies that met the eligibility criteria were extracted by one reviewer and this was then checked by a second reviewer.</p>
<p><strong>Evidence Classification and Recommendation Levels</strong></p>
<p>Both the quality of the evidence and the eventual strength of the recommendations generated by this evidence were graded according to a three-tiered system for assessing studies addressing diagnostic testing as approved by the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Joint Guidelines Committee (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field). </p>
<p>Articles were chosen that allowed for the calculation of two stereotactic brain biopsy (SBB)-specific parameters: diagnostic yield and diagnostic accuracy. In order to achieve Class I or II evidence, a well-designed SBB study had to calculate sensitivity and specificity values. Of note, given the inherent hemorrhage risk with brain biopsy, designing a double-blinded study with controls has yet to be done.</p>
<p>Diagnostic yield is the percent of stereotactic biopsies that obtain a histopathologic diagnosis. The &quot;gold standard&quot; for diagnostic yield was defined as the ability to obtain diagnostic tissue. Therefore, for diagnostic yield to achieve Class I or II evidence rating, a well-designed SBB trial would have to compare a targeting modality (i.e., surgical or imaging) with a SBB specimen.</p>
<p>Diagnostic accuracy is the proportion of stereotactic biopsies that agree with the &quot;gold standard&quot; of surgical resection or autopsy. For diagnostic accuracy, the Task Force defined the &quot;gold standard&quot; to be the comparison with brain tissue obtained at a subsequent craniotomy or at autopsy. Therefore, for diagnostic accuracy to achieve Class I or II evidence rating, a well-designed SBB trial would have to compare SBB with a surgical resection or autopsy brain specimen. Interestingly, surgical or autopsy specimens would never result in an incorrect histopathologic diagnosis, explaining why the calculated specificity and negative predictive values will always be 0%.</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong><span style=&quot;text-decoration: underline;&quot;>Guideline Panel Development</span></strong></p>
<p>Recognizing the serious nature of low grade gliomas along with the lack of consensus among various treatment options, the Joint Tumor Section of the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS) recommended that evidence-based guidelines be developed as a top priority, for the diagnosis, management and treatment of low grade glioma patients. The objectives of these guidelines are to establish the best evidence-based management of low grade gliomas in terms of imaging diagnosis, use of surgical biopsy and resection, assessment of tumor pathology, administration of systemic chemotherapy, and administration of radiation therapy. Because these tumors dependably recur or progress despite standard therapy, the Joint Tumor Section also recommended an evidence-based guideline be developed for progressive low grade gliomas and that information on promising emerging therapies be assessed in the same manner to determine the possible application of these findings.</p>
<p>Having identified the topical objectives, the Guidelines Committee of the Joint Tumor Section then recruited experts in the field from each of the parent organizations as lead writers of each section. These writers, in turn, recruited experts in non-neurosurgical specialties relevant to the field of management and therapy chosen. Writers were provided training on the method of guideline development as used in this guideline set by written methods and instructions. The senior authors and CNS Guidelines Manager then worked with them on a step by step basis to confirm that the methods were followed as the literature was collected, assessed and documents developed. When writers were approached and preliminarily agreed to participate they were asked to complete a formal conflict of interest questionnaire confirming the appropriateness of their participation. At that point they also agreed to report any new conflicts of interest that might develop during the writing process. In this manner a multidisciplinary panel of writers referred to as the Low Grade Glioma Guidelines Task Force was assembled, with significant administrative, logistical and analytical support from the national CNS Guidelines Committee. The method of this evidence-based clinical practice parameter guideline has been written in a manner to be as transparent as possible using published assessment criteria. </p>
<p><span style=&quot;text-decoration: underline;&quot;><strong>Topic Range of This Systematic Review and Clinical Practice Guideline</strong></span></p>
<p>Having identified writing groups for each topic, the members designed questions to allow assessment of the literature in a manner that would provide guidance for management of low grade gliomas. These questions are presented at the beginning of each of the eight guideline chapters spanning the topics of imaging assessment, diagnostic biopsy, surgical resection, tumor evaluation by standard neuropathology and molecular techniques, radiation therapy, chemotherapy, emerging therapies and treatment of recurrent or progressive low grade gliomas.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Guideline Panel Consensus</span></strong></p>
<p>Multidisciplinary writing groups were created for each section based on author expertise, in order to address each of the disciplines and particular areas of therapy selected for these clinical guidelines. Each group was involved with literature selection, creation and editing of the evidence tables and scientific foundations for their specific section and discipline. Using this information, the writing groups then drafted the recommendations in answer to the questions formulated at the beginning of the process, culminating in the clinical practice guideline for their respective discipline. The draft guidelines were then circulated to the entire clinical guideline panel to allow for multidisciplinary feedback, discussion, and ultimately approval.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>See the &quot;Rating Scheme for the Strength of the Evidence&quot; field.</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="External Peer Review"/>
      <fieldvalue value="Internal Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong><span style=&quot;text-decoration: underline;&quot;>Approval Process</span></strong></p>
<p>The completed evidence-based clinical practice guidelines for the management of low grade gliomas were presented to the Joint Guidelines Committee (JGC) of the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) for review. The reviewers for the JGC were vetted by the <em>Journal of Neuro-oncology</em> for suitability and expertise to serve as reviewers for the purposes of publication in that journal also. The final product was then approved and endorsed by the executive committees of both the AANS and CNS prior to publication in the <em>Journal of Neuro-oncology</em>.</p>
<p>The funding agencies (CNS Executive Committee and AANS/CNS Joint Tumor Section Executive Committee) were permitted to review these guidelines only after the Joint Guidelines Committee had completed its extensive review, critique and ultimate approval process; the funding groups then were limited to whether or not to endorse or reject this body of work but substantive changes were not allowed.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Multiple studies underscore the importance of obtaining pathologic diagnosis prior to instituting treatment. Although surgical resection is the &quot;gold standard&quot; for histopathologic diagnosis, surgery may not be feasible in patients with tumors in difficult locations or patients too ill for craniotomy. In these cases, stereotactic brain biopsy (SBB) has been utilized. </p></div>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Morbidity and mortality related to biopsy. There is higher risk of biopsy-related morbidity in patients with diabetes mellitus, and thalamic and basal ganglia locations. </li>
    <li>Diagnostic inaccuracy is related to sampling error that can result in under- and over-estimation of tumor grade, as well as misdiagnosis. </li>
</ul>"/>
    </field>
  </section>
  <section secid="430" ordby="800" name="Contraindications">
    <field fieldid="144" ordby="805" id="431" name="Contraindications" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Contraindications to stereotactic brain biopsy (SBB) in one reported study included: platelets &amp;lt;50,000/mL, international normalized ratio (INR) &amp;gt;1.5, coagulopathy, patients unable to cooperate with local anesthesia, patients unable to tolerate general anesthesia, lesions in which open or endoscopic surgery deemed less risky (e.g., pineal region).</p></div>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The information in these guidelines reflects the current state of knowledge at the time of completion. Each section is designed to provide an accurate review of the subject matter covered. These guidelines are disseminated with the understanding that the recommendations by the authors and consultants who have collaborated in their development are not meant to replace the individualized care and treatment advice from a patient's physician(s). If medical advice or assistance is required, the services of a competent physician should be sought. The proposals contained in these guidelines may not be suitable for use in all circumstances. The choice to implement any particular recommendation contained in these guidelines must be made by a managing physician in light of the situation in each particular patient and on the basis of existing resources.</p></div>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>An implementation strategy was not provided.</p></div>"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Living with Illness"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Ragel BT, Ryken TC, Kalkanis SN, Ziu M, Cahill D, Olson JJ. The role of biopsy in the management of patients with presumed diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015 Dec;125(3):481-501. [64 references] <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26530259&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2015 Dec"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="American Association of Neurological Surgeons - Medical Specialty Society"/>
      <fieldvalue value="Congress of Neurological Surgeons - Professional Association"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>These guidelines were funded exclusively by the Congress of Neurological Surgeons (CNS) Guidelines Committee, with no funding from any outside commercial sources. Development of this set of evidence-based clinical practice guidelines was editorially independent from the funding agencies. </p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Joint Guidelines Committee</p>
<p>Low Grade Glioma Guidelines Task Force</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><em>Authors</em>: Brian T. Ragel, Rebound Orthopedics and Neurosurgery, Vancouver, WA, USA; Timothy C. Ryken, Department of Neurosurgery, University of Kansas Medical Center, Kansas City, KS, USA; Steven N. Kalkanis, Department of Neurosurgery, Henry Ford Health System, Detroit, MI, USA; Mateo Ziu, Department of Neurosurgery, Seton Brain and Spine Institute, Austin, TX, USA; Daniel Cahill, Massachusetts General Hospital, Boston, MA, USA; Jeffrey J. Olson, Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><span style=&quot;text-decoration: underline;&quot;><strong>Conflict of Interest</strong></span></p>
<p>Low Grade Glioma Guidelines Task Force members were required to report all possible conflicts of interest (COIs) prior to beginning work on the guideline, using the COI disclosure form of the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Joint Guidelines Committee, including potential COIs that are unrelated to the topic of the guideline. The CNS Guidelines Committee and Guideline Task Force Chair reviewed the disclosures and either approved or disapproved the nomination. The CNS Guidelines Committee and Guideline Task Force Chair may approve nominations of Task Force Members with possible conflicts and address this by restricting the writing and reviewing privileges of that person to topics unrelated to the possible COIs.</p>
<p><span style=&quot;text-decoration: underline;&quot;><strong>Disclosures</strong></span></p>
<p>Dr. Kalkanis is a consultant for Arbor and Varian. Dr. Olson is a consultant for the American Cancer Society; has received research funding from the National Cancer Institute, Genentech, and Millennium; and has received investigational drug provision from Merck.</p></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Available from the <a href=&quot;http://link.springer.com/article/10.1007/s11060-015-1866-2&quot; title=&quot;Journal of Neuro-Oncology Web site&quot;>Journal of Neuro-Oncology Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following are available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Rock J. Low grade glioma guidelines: foreword. J Neurooncol. 2015 Dec;125(3):447-8. Available from the <a href=&quot;http://link.springer.com/article/10.1007/s11060-015-1824-z&quot; title=&quot;Journal of Neuro-Oncology Web site&quot;>Journal of Neuro-Oncology Web site</a>. </li>
    <li>Olson JJ, Kalkanis SN, Ryken TC. Evidence-based clinical practice parameter guidelines for the treatment of adults with diffuse low grade glioma: introduction and methods. J Neurooncol. 2015 Dec;125(3):449-56. Available from the <a href=&quot;http://link.springer.com/article/10.1007/s11060-015-1847-5&quot; title=&quot;Journal of Neuro-Oncology Web site&quot;>Journal of Neuro-Oncology Web site</a>. </li>
    <li>Congress of Neurological Surgeons (CNS). Guideline development methodology: endorsed by the American Association of Neurological Surgeons (AANS), the Congress of Neurological Surgeons (CNS), and the AANS/CNS Joint Guideline Committee. Schaumburg (IL): Congress of Neurological Surgeons (CNS); 2012 Feb. 12 p. [2 references]. Available from the <a href=&quot;https://www.cns.org/sites/default/files/jgcguidelinedevelopmentmethodology.pdf&quot; title=&quot;Congress of Neurological Surgeons Web site&quot;>Congress of Neurological Surgeons Web site</a>. </li>
</ul></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on July 7, 2016. The information was not verified by the guideline developer. This summary was updated by ECRI Institute on February 15, 2017 following the U.S. Food and Drug Administration advisory on general anesthetic and sedation drugs.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 20:02:33 Jul 12, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 18:56:10 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 92.026 (3)
  esindex: 0.007
  captures_list: 117.117
  CDXLines.iter: 12.54 (3)
  PetaboxLoader3.datanode: 103.505 (4)
  exclusion.robots: 0.501
  exclusion.robots.policy: 0.475
  RedisCDXSource: 5.867
  PetaboxLoader3.resolve: 312.613
  load_resource: 363.065
-->